Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IO Biotech, Inc.IOBT · Entity 8764 | Chief Financial Officer | November 04, 2021 | November 08, 2021 |
| Rezolute, Inc.RZLT · Entity 1990 | Chief Financial Officer | July 31, 2019 | September 16, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IO Biotech, Inc.
Report date November 04, 2021 · Filed November 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2031-11-04 | Direct | 69,469 |
Reported balance
After 2021-11-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-04 · Grant · Acquired 69,469 · Balance 69,469 F1: These options vest 25% on the one-year anniversary of the vesting commencement date of November 4, 2021, and then in 1/48 monthly increments thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause or by the reporting person within 24 months of a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest 25% on the one-year anniversary of the vesting commencement date of November 4, 2021, and then in 1/48 monthly increments thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause or by the reporting person within 24 months of a change of control.
Rezolute, Inc.
Report date July 31, 2019 · Filed September 16, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2029-07-31 | Direct | 3,000,000 |
Reported balance
After 2019-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-31 · Grant · Acquired 3,000,000 · Balance 3,000,000 F1: 500,000 of the options is fully exercisable as of the date of grant. Vesting of 1,500,000 options will occur in thirty-six equal installments beginning on the first day of each month thereafter, such grant vested in full after 3 years. The remaining 1,000,000 options vest equally over a 36-month period following certain performance and market price criteria. Such remaining options will not necessarily vest or convert into non-derivative securities to be beneficially owned by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: 500,000 of the options is fully exercisable as of the date of grant. Vesting of 1,500,000 options will occur in thirty-six equal installments beginning on the first day of each month thereafter, such grant vested in full after 3 years. The remaining 1,000,000 options vest equally over a 36-month period following certain performance and market price criteria. Such remaining options will not necessarily vest or convert into non-derivative securities to be beneficially owned by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2021 Filed Nov 8, 2021 23:37 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 69,469 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001140361-21-037042 · form4.xml · derivative · entry 1 Vendola Keith A. · CIK 0001740994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,469 Underlying: Common Stock · 69,469 shares Expires 2031-11-04 F1 · derivative.exercise_date: These options vest 25% on the one-year anniversary of the vesting commencement date of November 4, 2021, and then in 1/48 monthly increments thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause or by the reporting person within 24 months of a change of control. Read SEC document |
| July 31, 2019 Filed Sep 16, 2019 21:16 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantStock Option (right to buy) · Derivative | 3,000,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001567619-19-018370 · doc1.xml · derivative · entry 1 Vendola Keith A. · CIK 0001740994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2029-07-31 F1 · derivative.exercise_date: 500,000 of the options is fully exercisable as of the date of grant. Vesting of 1,500,000 options will occur in thirty-six equal installments beginning on the first day of each month thereafter, such grant vested in full after 3 years. The remaining 1,000,000 options vest equally over a 36-month period following certain performance and market price criteria. Such remaining options will not necessarily vest or convert into non-derivative securities to be beneficially owned by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.